Historical prostate cancer screening and treatment outcomes from a single institution

Clinical Medicine and Research

Volumn 10, Issue 3, 2012, Pages 97-105

  Cross, Deanna S ^a   Ritter, Mark ^b   Reding, Douglas J ^a  

^a MARSHFIELD CLINIC   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Outcomes; Prostate cancer; PSA testing; Treatment

Indexed keywords

HORMONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; BRACHYTHERAPY; CANCER GRADING; CANCER REGISTRY; CANCER SCREENING; CANCER STAGING; CAUSE OF DEATH; ELECTRONIC MEDICAL RECORD; EVENT FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HEALTH SERVICE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PHOTON THERAPY; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UNITED STATES;

AGE FACTORS; AGED; DISEASE-FREE SURVIVAL; ELECTRONIC HEALTH RECORDS; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84865328451     PISSN: 15394182     EISSN: 15546179     Source Type: Journal    
DOI: 10.3121/cmr.2011.1042     Document Type: Article

References (37)

1. Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC, van Ballegooijen M, Goede SL, Ries LA. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010; 16:544-573.
2. Committee on Comparative Effectiveness Research Prioritization. Institute of medicine, initial national priorities for comparative effectiveness research. Washington, D.C.: National Academies Press; 2009.
3. Penson DF, Rossignol M, Sartor AO, Scardino PT, Abenhaim LL. Prostate cancer: epidemiology and health-related quality of life. Urology 2008; 72:S3-S11.
4. van Leeuwen PJ, Connolly D, Gavin A, Roobol MJ, Black A, Bangma CH, Schröder FH. Prostate cancer mortality in screen and clinically detected prostate cancer: Estimating the screening benefit. Eur J Cancer. 2010; 46:377-383.
5. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 2009; 101:1325-1329.
6. Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery E, Barry MJ. Screening, treatment, and prostate cancer mortality in the Seattle area and Connecticut: fifteen-year follow-up. J Gen Intern Med 2008; 23:1809-1814.
7. Veltri RW, Miller MC, O'dowd GJ, Partin AW. Impact of age on total and complexed prostate-specific antigen cutoffs in a contemporary referral series of men with prostate cancer. Urology 2002; 60:47-52.
8. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P. Prostate specific antigen best practice statement: 2009 update. J Urol 2009; 182:2232-2241.
9. Witte JS. Personalized prostate cancer screening: improving PSA tests with genomic information. Sci Transl Med 2010; 2:62ps55.
10. US Preventative Services Task Force. Screening for prostate cancer. Available at http://www. uspreventiveservicestaskforce.org/uspstf/uspsprca.htm. Accessed June 11, 2012.
11. Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, Gleitsmann K, Koenig HC, Lam C, Maltz A, Rugge JB, Lin K. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155:762-771.
12. Barry MJ. Screening for prostate cancer--the controversy that refuses to die. N Engl J Med 2009; 360:1351-1354.
13. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360:1320-1328.
14. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD; PLCO Project Team. Mortality results from a randomized prostatecancer screening trial. N Engl J Med 2009; 360:1310-1319. Erratum in: N Engl J Med 2009; 360:1797.
15. Farwell WR, Linder JA, Jha AK. Trends in prostate-specific antigen testing from 1995 through 2004. Arch Intern Med 2007; 167:2497-2502.
16. Ross LE, Berkowitz Z, Ekwueme DU. Use of the prostatespecific antigen test among U.S. men: findings from the 2005 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev 2008; 17:636-644.
17. Jereczek-Fossa BA, Curigliano G, Orecchia R. Systemic therapies for non-metastatic prostate cancer: review of the literature. Onkologie 2009; 32:359-363.
18. Ladjevardi S, Sandblom G, Berglund A, Varenhorst E. Tumour grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer. Eur Urol 2010; 57:631-638.
19. Dahm P, Yeung LL, Chang SS, Cookson MS. A critical review of clinical practice guidelines for the management of clinically localized prostate cancer. J Urol 2008; 180:451-459; discussion 460.
20. Namiki S, Arai Y. Health-related quality of life in men with localized prostate cancer. Int J Urol 2010;17:125-138
21. Gomella LG, Johannes J, Trabulsi EJ. Current prostate cancer treatments: effect on quality of life. Urology 2009; 73:S28-S35.
22. Adkison JB, Ritter MA. Prostate cancer-which treatment to choose? Arch Intern Med 2008; 168:1352; author reply 1353.
23. Biagioli MC, Hoffe SE. Emerging technologies in prostate cancer radiation therapy: improving the therapeutic window. Cancer Control 2010; 17:223-232.
24. Lin DW, Porter M, Montgomery B. Treatment and survival outcomes in young men diagnosed with prostate cancer: a population-based cohort study. Cancer 2009; 115:2863-2871.
25. Bock CH, Peyser PA, Montie JE, Cooney KA. Decreasing age at prostate cancer diagnosis over successive generations in prostate cancer families. Prostate 2005; 64:60-66.
26. Shao YH, Demissie K, Shih W, Mehta AR, Stein MN, Roberts CB, Dipaola RS, Lu-Yao GL. Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst 2009; 101:1280-1283.
27. Pashayan N, Pharoah P, Neal DE, Hamdy F, Donovan J, Martin RM, Greenberg D, Duffy SW. Stage shift in PSA-detected prostate cancers-effect modification by Gleason score. J Med Screen 2009; 16:98-101.
28. Grubb RL 3rd, Pinsky PF, Greenlee RT, Izmirlian G, Miller AB, Hickey TP, Riley TL, Mabie JE, Levin DL, Chia D, Kramer BS, Reding DJ, Church TR, Yokochi LA, Kvale PA, Weissfeld JL, Urban DA, Buys SS, Gelmann EP, Ragard LR, Crawford ED, Prorok PC, Gohagan JK, Berg CD, Andriole GL. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int 2008; 102:1524-1530.
29. Pelzer AE, Colleselli D, Bektic J, Schaefer G, Ongarello S, Schwentner C, Pallwein L, Mitterberger M, Steiner E, Bartsch G, Horninger W. Clinical and pathological features of screen vs non-screen-detected prostate cancers: is there a difference? BJU Int 2008; 102:24-27.
30. Postma R, Schröder FH, van Leenders GJ, Hoedemaeker RF, Vis AN, Roobol MJ, van der Kwast TH. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Section Rotterdam. A comparison of two rounds of screening. Eur Urol 2007; 52:89-97.
31. Hamilton AS, Albertsen PC, Johnson TK, Hoffman R, Morrell D, Deapen D, Penson DF. Trends in the treatment of localized prostate cancer using supplemented cancer registry data. BJU Int 2011; 107:576-584.
32. Schymura MJ, Kahn AR, German RR, Hsieh MC, Cress RD, Finch JL, Fulton JP, Shen T, Stuckart E. Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1). BMC Cancer 2010; 10:152.
33. Hu JC, Hevelone ND, Ferreira MD, Lipsitz SR, Choueiri TK, Sanda MG, Earle CC. Patterns of care for radical prostatectomy in the United States from 2003 to 2005. J Urol 2008; 180:1969-1674.
34. Colberg JW, Decker RH, Khan AM, McKeon A, Wilson LD, Peschel RE. Surgery versus implant for early prostate cancer: results from a single institution, 1992-2005. Cancer J 2007; 13:229-232.
35. Kupelian PA, Ciezki J, Reddy CA, Klein EA, Mahadevan A. Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2008; 71:16-22.
36. Welz S, Nyazi M, Belka C, Ganswindt U. Surgery vs. radiotherapy in localized prostate cancer. Which is best? Radiat Oncol 2008; 3:23.
37. Merglen A, Schmidlin F, Fioretta G, Verkooijen HM, Rapiti E, Zanetti R, Miralbell R, Bouchardy C. Short-and long-term mortality with localized prostate cancer. Arch Intern Med. 2007; 167:1944-1950.